New Breast Cancer Research Tool Looks at Tumor Biology, Predicts Treatment Response

New Breast Cancer Research Tool Looks at Tumor Biology, Predicts Treatment Response
NanoString launched a new research panel to allow for a more rapid and complete view of breast cancer and its associated immune response. The new Breast Cancer 360 (BC 360) panel will enable researchers to measure variables related to tumor progression and treatment response, the company says. "Breast cancer is a complex disease with many distinct subtypes, each having its own unique biology," Alessandra Cesano, chief medical officer of NanoString, said in a press release. "While cancer research and drug development have historically focused on understanding the biology of the tumor itself, the field is moving toward a more holistic approach that goes beyond the tumor to examine the role that the tumor microenvironment and host immune response play," Cesano said. The BC 360 Panel is part of NanoString's portfolio of cancer research panels for translational research, which includes the PanCancer Immuno-Oncology (IO) 360 Panel. "We created the Breast Cancer 360 Panel to anticipate the needs of translational researchers in their quest to understand the implications of heterogeneity in breast cancer for drug development and patient management," Cesano added. The
Subscribe or to access all post and page content.